Repare Therapeutics Agrees To Acquisition As Board Cites Best Path For Stakeholder Value

Core Points - XenoTherapeutics Inc. and Xeno Acquisition Corp have agreed to acquire Repare Therapeutics Inc. for a cash payment of $1.82 per Common Share based on Repare's cash balance at closing [1] - Each Repare shareholder will also receive a non-transferable contingent value right for each Common Share, entitling them to certain cash payments [2] - Repare's Board of Directors believes the transaction maximizes shareholder value and provides cash payments along with future participation in milestones and royalties from partnerships [3] - The transaction is expected to close in the first quarter of 2026 [3] Financial Details - The arrangement includes a termination fee of $2 million payable by Repare Therapeutics [4] - Repare has out-licensed its discovery platforms to DCx Biotherapeutics for upfront and near-term payments totaling $4 million, along with a 9.99% equity position in DCx [5] - Repare entered into an exclusive licensing agreement with Debiopharm International for lunresertib, which includes a $10 million upfront payment and potential milestone payments up to $257 million [6] - RPTX stock increased by 25.15% to $2.065 in premarket trading [6]